Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agios Pharmaceuticals, Inc. (AGIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. As a Delaware corporation with common stock traded on the Nasdaq Global Select Market, Agios submits current and periodic reports to the U.S. Securities and Exchange Commission that document its financial condition, governance decisions, and material events.
For investors analyzing AGIO, key filings include Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s rare disease business, risk factors, research and development spending, and details on commercial-stage activities around products such as PYRUKYND (mitapivat) and AQVESME (mitapivat). Form 8-K current reports capture material developments, including quarterly financial results, stock incentive plan amendments, director elections, regulatory updates, and safety-related communications.
This page also surfaces proxy statements and exhibits referenced in filings, which can provide insight into stock incentive plans, non-employee director compensation, and shareholder voting outcomes. Where applicable, Form 4 and other ownership filings can be used to review insider transactions by directors and officers.
Stock Titan enhances these SEC documents with AI-powered summaries that explain complex sections in plain language, helping users quickly understand what each filing means for Agios’ rare disease strategy, PK activation franchise, and capital allocation. Real-time updates from EDGAR ensure that new AGIO filings appear promptly, while structured access to 10-Ks, 10-Qs, 8-Ks, and ownership reports allows for efficient due diligence on this commercial-stage biopharmaceutical company.
Agios Pharmaceuticals (AGIO) Q2-25 10-Q highlights:
- Revenue: PYRUKYND® sales rose 45% YoY to $12.5 m for the quarter and 26% YoY to $21.2 m YTD.
- Losses: Operating loss widened to $233.7 m YTD (-18%) as R&D spend climbed 13% to $164.7 m and SG&A 31% to $87.4 m. Net loss YTD was $201.3 m (-$3.49/sh) vs $177.7 m (-$3.14/sh) in 2024.
- Cash runway: Cash, cash equivalents and marketable securities total $1.31 bn (-$143 m from YE-24) after $188.6 m operating cash burn; management still projects ≥12-month liquidity.
- Balance sheet: Equity fell to $1.37 bn (-11%) on growing accumulated deficit (-$350 m). No debt reported.
- Clinical & regulatory: FDA accepted sNDA for PYRUKYND in α/β-thalassemia (PDUFA 7-Sep-25); EMA and GCC filings submitted. Phase 3 ENERGIZE & ENERGIZE-T met primary/secondary endpoints but revealed hepatocellular injury risk—monthly LFT monitoring now included in label & protocols.
- Pipeline spend: $10 m milestone paid to Alnylam for TMPRSS6 siRNA (AG-236). Phase 2/3 RISE-UP for SCD ongoing.
- Outlook: Company remains pre-profit; commercialization of PYRUKYND beyond PK-deficiency and retained earn-out on vorasidenib royalties are key value drivers.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) filed an 8-K announcing the election of Jay Backstrom, M.D., MPH, to its Board of Directors. The Board approved his appointment on 3 July 2025, effective 8 July 2025, as a Class III director serving until the 2028 annual meeting.
Compensation package under the non-employee director policy:
- Annual cash retainers: $50,000 for board service and $7,500 for Science & Technology Committee duties.
- Equity awards effective 8 July 2025: (i) non-statutory stock option with a Black-Scholes grant-date value of $472,500; (ii) restricted stock units valued at $157,500. The option strike price equals the closing market price on the grant date. Vesting: 25 % of options after one year, remainder monthly over 36 months; RSUs vest one-third annually over three years.
- Standard reimbursement of reasonable travel expenses.
Dr. Backstrom will also sign the company’s standard indemnification agreement. The filing states there are no related-party transactions or other arrangements connected to his selection.
The disclosure is limited to governance matters; it does not include financial results or operational updates.
Schedule 13G filing: Bellevue Group AG and its wholly-owned subsidiary Bellevue Asset Management AG have disclosed a new beneficial ownership position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO).
- Stake size: 3,515,150 common shares, representing 6.1 % of the outstanding class as of the triggering date 06 / 01 / 2025.
- Voting & dispositive power: The reporting persons hold shared voting and dispositive power over the entire position; they report zero sole voting/dispositive power.
- Reporting entities: Bellevue Group AG (parent holding company, Switzerland) and Bellevue Asset Management AG (investment manager, Switzerland) filed jointly.
- Purpose: The securities were acquired and are held in the ordinary course of business, not for the purpose of influencing control, as certified in Item 10.
- Form details: Filed 07 / 07 / 2025 under Rule 13d-1(b); CUSIP 00847X104; security class – common stock.
This disclosure introduces Bellevue as a >5 % institutional holder in Agios. While no strategic intentions are indicated, the filing may signal incremental institutional confidence and can affect perceptions of the shareholder base composition.
FAQ
What is the current stock price of Agios Pharmaceuticals (AGIO)?
What is the market cap of Agios Pharmaceuticals (AGIO)?
